tbuckley/cabot-search huggingface dataset:
Anxiolytic Effects of Chronic Intranasal Oxytocin on Neural Responses to Threat Are Dose-Frequency Dependent
Authors: Juan Kou, Yingying Zhang, Feng Zhou, Zhao Gao, Shuxia Yao, Weihua Zhao, Hong Li, Yi Lei, Shan Gao, Keith M. Kendrick, Benjamin Becker
Journal: Psychotherapy and Psychosomatics (2022)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Anxiety disorders are prevalent mental conditions characterized by exaggerated anxious arousal and threat reactivity. Animal and human studies suggest an anxiolytic potential of the neuropeptide oxytocin (OT), yet, while a clinical application will require chronic administration protocols, previous human studies have exclusively focused on single-dose (acute) intranasal OT effects. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To facilitate the translation of the potential anxiolytic mechanism of OT into clinical application, we determined whether the anxiolytic effects of OT are maintained with repeated (chronic) administration or are influenced by dose frequency and trait anxiety. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In a pre-registered double-blind randomized placebo-controlled pharmaco-fMRI trial the acute (single dose) as well as chronic effects of two different dose frequencies of OT (OT administered daily for 5 days or every other day) on emotional reactivity were assessed in &lt;i&gt;n&lt;/i&gt; = 147 individuals with high versus low trait anxiety (ClinicalTrials.gov ID: NCT03085654). &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; OT produced valence, dose frequency, and trait anxiety-specific effects, such that the low-frequency (intermittent) chronic dosage specifically attenuated a neural reactivity increase in amygdala-insula-prefrontal circuits observed in the high anxious placebo-treated subjects in response to threatening but not positive stimuli. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; The present trial provides the first evidence that low-dose frequency chronic intranasal OT has the potential to alleviate exaggerated neural threat reactivity in subjects with elevated anxiety levels, suggesting a treatment potential for anxiety disorders.
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
Authors: Pieter Jelle Visser, Lianne M. Reus, Johan Gobom, Iris Jansen, Ellen Dicks, Sven J. van der Lee, Magda Tsolaki, Frans R. J. Verhey, Julius Popp, Pablo Martinez-Lage, Rik Vandenberghe, Alberto Lleó, José Luís Molinuevo, Sebastiaan Engelborghs, Yvonne Freund-Levi, Lutz Froelich, Kristel Sleegers, Valerija Dobricic, Simon Lovestone, Johannes Streffer, Stephanie J. B. Vos, Isabelle Bos, August B. Smit, Kaj Blennow, Philip Scheltens, Charlotte E. Teunissen, Lars Bertram, Henrik Zetterberg, Betty M. Tijms, August B. Smit, Kaj Blennow, Philip Scheltens, Charlotte E. Teunissen, Lars Bertram, Henrik Zetterberg, Betty M. Tijms
Journal: Molecular Neurodegeneration (2022)

Abstract Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. This suggests that t-tau levels may be driven by other mechanisms as well. Because tau pathophysiology is emerging as treatment target for AD, we aimed to clarify molecular processes associated with CSF t-tau levels. Methods We performed a proteomic, genomic, and imaging study in 1380 individuals with AD, in the preclinical, prodromal, and mild dementia stage, and 380 controls from the Alzheimer’s Disease Neuroimaging Initiative and EMIF-AD Multimodality Biomarker Discovery study. Results We found that, relative to controls, AD individuals with increased t-tau had increased CSF concentrations of over 400 proteins enriched for neuronal plasticity processes. In contrast, AD individuals with normal t-tau had decreased levels of these plasticity proteins and showed increased concentrations of proteins indicative of blood–brain barrier and blood-CSF barrier dysfunction, relative to controls. The distinct proteomic profiles were already present in the preclinical AD stage and persisted in prodromal and dementia stages implying that they reflect disease traits rather than disease states. Dysregulated plasticity proteins were associated with SUZ12 and REST signaling, suggesting aberrant gene repression. GWAS analyses contrasting AD individuals with and without increased t-tau highlighted several genes involved in the regulation of gene expression. Targeted analyses of SNP rs9877502 in GMNC , associated with t-tau levels previously, correlated in individuals with AD with CSF concentrations of 591 plasticity associated proteins. The number of APOE-e4 alleles, however, was not associated with the concentration of plasticity related proteins. Conclusions CSF t-tau levels in AD are associated with altered levels of proteins involved in neuronal plasticity and blood–brain and blood-CSF barrier dysfunction. Future trials may need to stratify on CSF t-tau status, as AD individuals with increased t-tau and normal t-tau are likely to respond differently to treatment, given their opposite CSF proteomic profiles.
Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
Authors: Andreas Seeber, Francesca Battaglin, Kai Zimmer, Florian Kocher, Yasmine Baca, Joanne Xiu, Gilbert Spizzo, Veronica Novotny-Diermayr, Dietmar Rieder, Alberto Puccini, Jeff Swensen, Michelle Ellis, Richard M. Goldberg, Axel Grothey, Anthony F. Shields, John L. Marshall, Benjamin A. Weinberg, Paul E. Sackstein, Kiat Hon Lim, Gek San Tan, Chadi Nabhan, W. Michael Korn, Arno Amann, Zlatko Trajanoski, Martin D. Berger, Emil Lou, Dominik Wolf, Heinz-Josef Lenz
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Gene fusions involving R-spondin (RSPOfp) and RNF43 mutations have been shown to drive Wnt-dependent tumor initiation in colorectal cancer. Herein, we aimed to characterize the molecular features of RSPOfp/RNF43 mutated (mut) compared with wild-type (WT) colorectal cancers to gain insights into potential rationales for therapeutic strategies. Experimental Design: A discovery cohort was classified for RSPOfp/RNF43 status using DNA/RNA sequencing and IHC. An independent cohort was used to validate our findings. Results: The discovery cohort consisted of 7,245 colorectal cancer samples. RSPOfp and RNF43 mutations were detected in 1.3% (n = 94) and 6.1% (n = 443) of cases. We found 5 RSPO fusion events that had not previously been reported (e.g., IFNGR1–RSPO3). RNF43-mut tumors were associated with right-sided primary tumors. No RSPOfp tumors had RNF43 mutations. In comparison with WT colorectal cancers, RSPOfp tumors were characterized by a higher frequency of BRAF, BMPR1A, and SMAD4 mutations. APC mutations were observed in only a minority of RSPOfp-positive compared with WT cases (4.4% vs. 81.4%). Regarding RNF43 mutations, a higher rate of KMT2D and BRAF mutations were detectable compared with WT samples. Although RNF43 mutations were associated with a microsatellite instability (MSI-H)/mismatch repair deficiency (dMMR) phenotype (64.3%), and a tumor mutation burden ≥10 mt/Mb (65.8%), RSPOfp was not associated with MSI-H/dMMR. The validation cohort replicated our genetic findings. Conclusions: This is the largest series of RSPOfp/RNF43-mut colorectal cancers reported to date. Comprehensive molecular analyses asserted the unique molecular landscape associated with RSPO/RNF43 and suggested potential alternative strategies to overcome the low clinical impact of Wnt-targeted agents and immunotherapy.
HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY PRESENTING AS A CEREBRAL VASCULAR ACCIDENT IN A YOUNG ADULT FEMALE.
Authors: William Lorson, Christopher Salmon, George Prousi, William Meeks, James Davis, Ninad M. Zaman, Meer Fakhry, Richard A. Edelson
Journal: Journal of the American College of Cardiology (2022)
Medical English as She is Wrote
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maybe Not an Acute Inferior Myocardial Infarction
Authors: Yi-Wei Cao, Hao-Yu Wu
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer
Authors: Jang-il Kim, Yireh Han, Changjin Lim, Jong-Ho Cheun, Ji Gwang Jung, Hong Kyu Kim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han
Journal: Cancer Research (2022)

Abstract Introduction : Latissimus dorsi mini-flap (LDMF) with breast conserving surgery (BCS) was introduced as a useful volume replacement technique when the tumor is located in upper or outer portion of breast and the tumor size is large requiring extensive excision of breast tissue. However few studies have assessed quality of life (QoL) and objective cosmetic outcome of LDMF in breast cancer surgery. We tried to evaluate those in patients who underwent BCS with or without LDMF. Methods : This study was a prospective, single-center cohort study of patients who underwent LDMF and BCS between 2011 and 2018. As a control, patients who underwent BCS without any volume replacement and the tumor size equal to or greater than 2.5cm on the upper or upper outer of the breast on preoperative imaging. Breast Q questionnaire and body photo were taken at least 1 year after surgery. Two breast surgeons and one plastic surgeon who did not performed LDMF assessed the cosmetic outcome of the patients with photo. Results : 62 patients were in the BCS with LDMF group and 58 patients were in BCS-only group. Pathologic tumor size was significantly larger in LDMF group than BCS-only group (LDMF 3.89cm vs BCS-only 2.92cm, p= 0.001 ). Psychosocial well-being (P= 0.024), physical well-being (P= 0.000), and satisfaction with surgeon (p= 0.006) were significantly better in the BCS-only group than in the LDMF group respectively. But, there were no significant difference in neither sexual well-being (p= 0.286) nor satisfaction for breast (p=0.278) between BCS and LDMF group. In the physicians assessment, there was no significant difference in the cosmetic outcome score between the two groups (LDMF 2.56/4 vs. BCS-only 2.58/4, p= 0.884). Conclusion : In conclusion, physician assessed cosmetic outcome of LDMF was equivalent to that of BCS without LDMF although the tumor size was significantly larger in patients with LDMF. Some inferiority of QoL might be due to postoperative pain or arm movement discomfort. We are planning to evaluate objective cosmetic results using BCCT.core software. Citation Format: Jang-il Kim, Yireh Han, Changjin Lim, Jong-Ho Cheun, Ji Gwang Jung, Hong Kyu Kim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han. Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-18-14.
Patients With Acute-on-Chronic Liver Failure Have Greater Healthcare Resource Utilization After Liver Transplantation
Authors: Vinay Sundaram, Christina C Lindenmeyer, Kirti Shetty, Robert S Rahimi, Atef Al-Attar, Gianina Flocco, Brett E Fortune, Cynthia Gong, Suryanarayana Challa, Haripriya Maddur, Janice H Jou, Michael Kriss, Lance L Stein, Alex H Xiao, Ross H Vyhmeister, Ellen W Green, Braidie Campbell, Andrew J Piscitello, William Cranford, Josh Levitsky, Constantine J Karvellas
Journal: Clinical Gastroenterology and Hepatology (2022)
CAROTID THERMAL HETEROGENEITY IS ASSOCIATED WITH CORONARY PLAQUE RUPTURE IN PATIENTS PRESENTING WITH ACUTE MYOCARDIAL INFARCTION
Authors: Pavlos Bounas, Andreas G. Synetos, Antonios Karanasos, Angelos Papanikolaou, Maria Drakopoulou, George Latsios, George Trantalis, Christopher D. Olympios, Dimitris Tousoulis, Konstantinos P. Toutouzas
Journal: Journal of the American College of Cardiology (2022)
ASSOCIATION OF ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY WITH COGNITIVE OUTCOMES IN HYPERTENSIVE, NON-DIABETIC PATIENTS: SPRINT MIND (SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL)
Authors: Rishi Rikhi, Agam Bansal, Elsayed Z. Soliman, Matthew J. Singleton
Journal: Journal of the American College of Cardiology (2022)
Abstract P3-19-26: The impact of post-mastectomy radiotherapy on the survival of breast cancer patients aged 70 years or older: A study based on SEER database
Authors: Jingyi Lin, Shiping Luo, Jie Zhang, Chuangui Song
Journal: Cancer Research (2022)

Abstract The impact of post-mastectomy radiotherapy on the survival of breast cancer patients aged 70 years or older: a study based on SEER databaseIntroduction: This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in the female aged 70 years or older diagnosed with breast cancer, which is still controversial.Methods: This retrospective study extracted data from the Surveillance, Epidemiology, and End Results (SEER) database. Women aged 70 years or more diagnosed with breast cancer between 2004 and 2016 following mastectomy were enrolled. Propensity score matching (PSM) was performed to reduce covariable imbalance. The univariable and multivariable analyses calculated the prognostic factors. Kaplan-Meier survival curves and multivariable Cox regression model were applied to compare breast cancer-specific survival (BCSS) and overall survival (OS) between two arms and among subgroups stratified by various clinicopathological factors. Results: Of the 27,636 female were eligible, 17.2%(n=4,747) received PMRT while 82,8%(n=22,889) not. By multivariable Cox analysis, radiotherapy was still founded to be independent prognostic factors for BCSS and OS. After 1:1 matching, PMRT were associated with significant improvement in BCSS and OS(p &amp;lt;0.001). By contrast, the BCSS and OS benefit from PMRT were not statistically significant in patients with T1 tumor and 1-3 positive lymph nodes(BCSS:HR = 0.716,95%CI 0.406-1.263,p = 0.249;OS:HR = 0.908,95%CI 0.648-1.270,p = 0.572), and the results were consistent in patients with T2 tumor and 1-3 positive lymph nodes(BCSS:HR = 0.866,95%CI 0.664-1.130,p = 0.289;OS:HR = 0.879,95%CI 0.732-1.055,p = 0.166). Stratified by grade, number of positive lymph nodes, and HR status, there were still not survival advantage of PMRT observed for patients with T1-2N1 breast cancer(all p&amp;gt;0.05).Conclusions: This study demonstrates that post-mastectomy radiotherapy has a definite role in improving the survival of females with elderly breast cancer. After a comprehensive assessment of the side effects and the quality of life, the omission of PMRT could be considered in patients with T1-2N1 breast cancer. Citation Format: Jingyi Lin, Shiping Luo, Jie Zhang, Chuangui Song. The impact of post-mastectomy radiotherapy on the survival of breast cancer patients aged 70 years or older: A study based on SEER database [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-19-26.
Comparison of Quality Measures for Detection of Neoplasia at Screening Colonoscopy
Authors: Paulina Wieszczy, Marek Bugajski, Wladyslaw Januszewicz, Maria Rupinska, Jakub Szlak, Malgorzata Pisera, Maryla H. Turkot, Maciej Rupinski, Urszula Wojciechowska, Joanna Didkowska, Jaroslaw Regula, Michal F. Kaminski
Journal: Clinical Gastroenterology and Hepatology (2022)
Abstract P1-13-02: Autophagy inhibition and senolytics to improve the response to fulvestrant + palbociclib in ER positive breast cancer
Authors: Ryan Michael Finnegan
Journal: Cancer Research (2022)

Abstract While anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her-2 negative metastatic breast cancer, relapse after remission continues to be a serious limitation to the effectiveness of these therapies. Although these combination therapies prolong progression-free survival compared to endocrine therapy alone, the growth-arrested state of residual tumor cells is clearly transient. Tumor cells that escape what might be considered a dormant or quiescent state and regain proliferative capacity often acquire resistance to further therapies. Our studies are based upon the observation that breast tumor cells arrested by Fulvestrant + Palbociclib enter into a state of autophagy/senescence from which a subpopulation ultimately escapes, potentially contributing to disease recurrence. ER+ MCF-7 breast tumor cells that were induced into autophagy/senescence by Fulvestrant + Palbociclib in vitro were exposed to the autophagy inhibitors, chloroquine and bafilomycin, prior to as well as after growth arrest. However, autophagy inhibition only moderately enhanced the response to therapy and, at best, delayed proliferative recovery. These findings were confirmed by genetic inhibition of autophagy. Despite clear entry into a state of senescence, the Bcl-xl inhibitor and senolytic ABT-263 (navitoclax) failed to promote tumor cell death; this is likely a consequence of high levels of survivin in the MCF-7 breast tumor cell line. However, the BET inhibitor, ARV-825, eliminated a large fraction of the senescent cell population and significantly delayed proliferative recovery. Cell death did not appear to be a consequence of increased apoptosis. Additionally, analysis of three database sets demonstrated that higher breast cancer expression of BRD4, a primary target of ARV-825, correlated with lower recurrence-free survival compared to patients with cancers expressing lower levels of BRD4. These studies indicate that administration of BET inhibitors, which are currently being investigated in multiple clinical trials, may potentially improve standard of care therapy in metastatic ER+ breast cancer patients by prolonging progression-free survival. Citation Format: Ryan Michael Finnegan. Autophagy inhibition and senolytics to improve the response to fulvestrant + palbociclib in ER positive breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-13-02.
SEX DIFFERENCES IN QUANTITATIVE COMPUTED TOMOGRAPHY CORONARY PLAQUE CHARACTERIZATION AND FRACTIONAL FLOW RESERVE: SUBSTUDY OF THE PACIFIC TRIAL
Authors: Donghee Han, Pepijn Van Diemen, Keiichiro Kuronuma, Andrew Lin, Priscilla McElhinney, Guadalupe Flores Tomasino, Caroline Park, Yuka Otaki, Alan Kwan, Evangelos Tzolos, Eyal Klein, Kajetan Grodecki, Benjamin Shou, Richard Rios, Nipun Manral, Sebastien Cadet, Ibrahim Danad, Roel Driessen, Daniel S. Berman, Piotr Slomka, Damini Dey, Paul Knaapen
Journal: Journal of the American College of Cardiology (2022)
Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3′UTR protect against ALS
Authors: Chen Eitan, Aviad Siany, Elad Barkan, Tsviya Olender, Kristel R. van Eijk, Matthieu Moisse, Sali M. K. Farhan, Yehuda M. Danino, Eran Yanowski, Hagai Marmor-Kollet, Natalia Rivkin, Nancy Sarah Yacovzada, Shu-Ting Hung, Johnathan Cooper-Knock, Chien-Hsiung Yu, Cynthia Louis, Seth L. Masters, Kevin P. Kenna, Rick A. A. van der Spek, William Sproviero, Ahmad Al Khleifat, Alfredo Iacoangeli, Aleksey Shatunov, Ashley R. Jones, Yael Elbaz-Alon, Yahel Cohen, Elik Chapnik, Daphna Rothschild, Omer Weissbrod, Gilad Beck, Elena Ainbinder, Shifra Ben-Dor, Sebastian Werneburg, Dorothy P. Schafer, Robert H. Brown, Pamela J. Shaw, Philip Van Damme, Leonard H. van den Berg, Hemali Phatnani, Eran Segal, Justin K. Ichida, Ammar Al-Chalabi, Jan H. Veldink, Johnathan Cooper-Knock, Kevin P. Kenna, Philip Van Damme, Leonard H. van den Berg, Eran Hornstein, Eran Hornstein
Journal: Nature Neuroscience (2022)
IMPACT OF NUTRITIONAL STATUS ON SHORT-AND LONG-TERM PROGNOSIS IN ACUTE MYOCARDIAL INFARCTION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Daisuke Kanda, Yoshiyuki Ikeda, Takuro Takumi, Kazuhiro Anzaki, Takeshi Sonoda, Akihiro Tokushige, Kenta Ohumare, Mitsuru Ohishi
Journal: Journal of the American College of Cardiology (2022)
Coronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction: A Prospective Cohort Study
Authors: Anda Bularga, John Hung, Marwa Daghem, Stacey Stewart, Caelan Taggart, Ryan Wereski, Trisha Singh, Mohammed N. Meah, Takeshi Fujisawa, Amy V. Ferry, Justin Chiong, William S. Jenkins, Fiona E. Strachan, Scott Semple, Edwin J.R. van Beek, Michelle Williams, Damini Dey, Chris Tuck, Andrew H. Baker, David E. Newby, Marc R. Dweck, Nicholas L. Mills, Andrew R. Chapman
Journal: Circulation (2022)

Type 2 myocardial infarction is caused by myocardial oxygen supply-demand imbalance, and its diagnosis is increasingly common with the advent of high-sensitivity cardiac troponin assays. Although this diagnosis is associated with poor outcomes, widespread uncertainty and confusion remain among clinicians as to how to investigate and manage this heterogeneous group of patients with type 2 myocardial infarction.
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
Authors: Analía Rearte, Juan Manuel Castelli, Ramiro Rearte, Nora Fuentes, Velen Pennini, Martina Pesce, Pilar Barcena Barbeira, Luciana Eva Iummato, Melisa Laurora, María Lucía Bartolomeu, Guido Galligani, María Del Valle Juarez, Carlos María Giovacchini, Adrián Santoro, Mariano Esperatti, Sonia Tarragona, Carla Vizzotti
Journal: The Lancet (2022)